Posted by Michael Wonder on 17 Oct 2025
Silver Creek Pharmaceuticals receives FDA fast track designation for Scp776 in acute ischaemic stroke
17 October 2025 - Silver Creek Pharmaceuticals today announced that the US FDA has granted fast track designation to scp776, its investigational therapy for acute ischaemic stroke, a condition with limited treatment options beyond reperfusion.
Scp776 is a multi-specific, targeted biologic designed to promote cell survival in injured tissue by inhibiting apoptosis—a key driver of injury following stroke.
